Mercier Johanna sold 3,000 GILEAD SCIENCES shares across three transactions priced from $143.69 to $145.29 per share. The transactions left her with 116,684 shares and represented about 2.5% of her prior shares holding, giving investors the reported size, pricing and resulting ownership position.
Key Highlights
- The transactions were reported under SEC transaction code S.
- Mercier Johanna is identified as GILEAD SCIENCES’ Chief Comm & Corp Aff Officer.
- The reported transactions took place on 15 September 2026.
GILEAD SCIENCES, INC. (NASDAQ: GILD) officer Mercier Johanna sold 3,000 shares across three transactions. The sales were priced between $143.69 and $145.29 per share, and the reported post-transaction holding was 116,684 shares.
Three Sales Cover $143.69 to $145.29
Each transaction carried SEC transaction code S. The transactions took place on 15 September 2026 and covered GILEAD SCIENCES shares at prices ranging from $143.69 to $145.29 per share. The combined transactions involved 3,000 shares. The reported prices apply on a per-share basis. The transaction details identify three separate sales rather than a single transaction.
Reported Holding After the Transactions
Mercier Johanna’s resulting position was 116,684 shares. The reported sale represented about 2.5% of her prior shares holding. That percentage is the stated comparison between the shares sold and her previous holding. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Gilead Sciences shares did Mercier Johanna sell?
A: Mercier Johanna sold a total of 3,000 GILEAD SCIENCES shares in three separate transactions. The Form 4 reports that all three sales occurred on 15 September 2026 under SEC transaction code S.
Q: What price range covered the Gilead Sciences insider sale?
A: The Gilead Sciences shares changed hands at prices ranging from $143.69 to $145.29 per share. The range covered all three reported transactions.
Q: How many Gilead Sciences shares did Mercier Johanna own afterward?
A: Mercier Johanna owned 116,684 GILEAD SCIENCES shares following the transactions. The sale represented about 2.5% of her prior shares holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.